Copertina

Investigation of Muscarinic Acetylcholine Receptor M3 Activation in Atomistic Detail: A Chemist's Viewpoint

Fuente: Wiley Open Access

Salvato in:

Dettagli Bibliografici
Autori principali:	Matthäus Drabek, Rolf Emmerich, Nuri Djulic, Moritz Bünemann, Martin Schlitzer, Peter Kolb
Natura:	Artículo Open Access
Pubblicazione:	Wiley 2024
Soggetti:	ChemMedChem
Accesso online:	Acceder al recurso
Tags:	Aggiungi Tag Nessun Tag, puoi essere il primo ad aggiungerne!!

Documenti analoghi

Synthesis and Evaluation of Fluorinated Peptidomimetics Enabling the Development of 18 F‐Labeled Radioligands Targeting Muscarinic Acetylcholine Receptor Subtype M3
di: Miguel A. Herrera‐Rueda, et al.
Pubblicazione: (2025)

How Should we Teach Medicinal Chemistry in Higher Education to Prepare Students for a Future Career as Medicinal Chemists and Drug Designers? – A Teacher's Perspective
di: Philipp Klahn
Pubblicazione: (2024)

Targeting Inflammatory and Oncogenic Pathways: Cyclooxygenase‐2, Epidermal Growth Factor Receptor, and p38 Mitogen‐Activated Protein Kinase Inhibition by Pyrazolone Derivatives
di: Sevde Nur Biltekin Kaleli, et al.
Pubblicazione: (2026)

Combinatorial Libraries of Bipodal Binders of the Insulin Receptor
di: Irena Selicharová, et al.
Pubblicazione: (2024)

Development of Carborane‐Based Halogenated Naphthyridinone‐Analogues as Cannabinoid Receptor Type 2 (CB 2 R) Ligands
di: Lea Ueberham, et al.
Pubblicazione: (2025)

Cover Feature: How Should we Teach Medicinal Chemistry in Higher Education to Prepare Students for a Future Career as Medicinal Chemists and Drug Designers? – A Teacher's Perspective (ChemMedChem 2/2025)
di: Philipp Klahn
Pubblicazione: (2025)

Discovery of Novel Aminopyrimidines as Selective EP2 Receptor Antagonists
di: Isabelle Lyothier, et al.
Pubblicazione: (2025)

Kainate Receptor Allosteric Modulators: State of the Art and Future Directions
di: Thomas Colson, et al.
Pubblicazione: (2026)

Identification of Novel and Selective GPR39 Receptor Antagonists for the Treatment of Acute Myocardial Ischemia
di: Agostino Cianciulli, et al.
Pubblicazione: (2025)

Structural Development of Androgen Receptor Antagonists Using Phenylferrocene Framework as a Hydrophobic Pharmacophore
di: Kotaro Ochiai, et al.
Pubblicazione: (2024)

Ligand‐Induced Conformational Plasticity of the CTLH E3 Ligase Receptor GID4
di: Daria Kotlarek, et al.
Pubblicazione: (2026)

Enhancing Drug Repurposing with Consensus Docking: Discovery of Novel Discoidin Domain Receptor 1 Inhibitors
di: Jochem Nelen, et al.
Pubblicazione: (2026)

Beyond the Toll‐Like Receptor 4. Structure‐Dependent Lipopolysaccharide Recognition Systems: How far are we?
di: Stefania De Chiara, et al.
Pubblicazione: (2025)

Lysophosphatidic Acid Receptor 1 (LPA1) Antagonists as Potential Migrastatics for Triple Negative Breast Cancer
di: Wenjie Liu, et al.
Pubblicazione: (2024)

Development of New Benzo[ b ]Thiophene‐2‐Carboxamide Derivatives as Advanced Glycation End‐Products Receptor (RAGE) Antagonists
di: Lisa Bonin, et al.
Pubblicazione: (2025)

Discovery and in vitro Evaluation of Novel Serotonin 5‐HT2A Receptor Ligands Identified Through Virtual Screening
di: Agata Zięba, et al.
Pubblicazione: (2024)

Development of a NanoBRET Assay Platform to Detect Intracellular Ligands for the Chemokine Receptors CCR6 and CXCR1
di: Max E. Huber, et al.
Pubblicazione: (2024)

Design, Synthesis, and Biological Assessment of Novel Aminobenzidazole Agonists Targeting the Stimulator of Interferon Genes (STING) Receptor Signaling Pathway for Oncology Immunotherapy
di: Yiqing Fan, et al.
Pubblicazione: (2025)

A New Series of Amino Alcohol Oxime Ethers as Activators of Human Brain Carbonic Anhydrases: Advances in Selective Activation of Human Carbonic Anhydrase VII
di: Camilla Mangini, et al.
Pubblicazione: (2026)

Machine Learning‐Driven Discovery of Structurally Related Natural Products as Activators of the Cardiac Calcium Pump SERCA2a
di: Carlos Cruz‐Cortés, et al.
Pubblicazione: (2025)

Insights Into Vepdegestrant (ARV‐471): The First‐in‐Class Estrogen Receptor Proteolysis‐Targeting Chimera Approaching Food and Drug Administration Approval for Breast Cancer
di: Chao Tang, et al.
Pubblicazione: (2026)

Front Cover: Structural Development of Androgen Receptor Antagonists Using Phenylferrocene Framework as a Hydrophobic Pharmacophore (ChemMedChem 6/2024)
di: Kotaro Ochiai, et al.
Pubblicazione: (2024)

Structure‐Based Discovery of Obeticholic Acid Derivatives as Novel Farnesoid X Receptor Partial Agonists with Improved Selectivity and Reduced Off‐Target Effects
di: Daniela Passeri, et al.
Pubblicazione: (2026)

Towards Multitargeted Ligands as Pain Therapeutics: Dual Ligands of the Cavα2δ‐1 Subunit of Voltage‐Gated Calcium Channel and the μ‐Opioid Receptor
di: Anita Wegert, et al.
Pubblicazione: (2024)

Nucleic Acid Materials‐Mediated Innate Immune Activation for Cancer Immunotherapy
di: Xinyu Xu, et al.
Pubblicazione: (2024)

Front Cover: Beyond the Toll‐Like Receptor 4. Structure‐Dependent Lipopolysaccharide Recognition Systems: How far are we? (ChemMedChem 6/2025)
di: Stefania De Chiara, et al.
Pubblicazione: (2025)

Synthesis and Biological Characterization of 4,4‐Difluoro‐3‐(phenoxymethyl)piperidine Scaffold as Dopamine 4 Receptor (D 4 R) Antagonist in vitro Tool compounds
di: Saeedeh Saeedi, et al.
Pubblicazione: (2025)

Exploring C2 and N6 Substituent Effects on Truncated 4′‐Thioadenosine Derivatives as Dual A2A and A3 Adenosine Receptor Ligands
di: Siddhi D. Naik, et al.
Pubblicazione: (2024)

Recent Development of Transition Metal Complexes as Chemotherapeutic Hypoxia Activated Prodrug (HAP)
di: K. Jagathesan, et al.
Pubblicazione: (2024)

A Nitroreductase‐Activatable Lapachol Against Bacillus subtilis Unveils Antimicrobial Specificity
di: Ivonne R. Lopez‐Miranda, et al.
Pubblicazione: (2026)

Recent Developments On Activatable Turn‐On Fluorogenic Donors of Hydrogen Sulfide (H2S)
di: Roopjyoti Misra, et al.
Pubblicazione: (2024)

Azologs of the Fatty Acid Mimetic Drug Cinalukast Enable Light‐Induced PPARα Activation
di: Minh Sai, et al.
Pubblicazione: (2024)

Green Light Activated Dual‐Action Pt(IV) Prodrug with Enhanced PDT Activity
di: Daniil Spector, et al.
Pubblicazione: (2025)

AMPK Activation by 2′‐Hydroxy‐2,4,5‐Trimethoxychalcone Derivatives in Podocyte Cells
di: Vu‐Duy Nguyen, et al.
Pubblicazione: (2025)

Front Cover: Development of a NanoBRET Assay Platform to Detect Intracellular Ligands for the Chemokine Receptors CCR6 and CXCR1 (ChemMedChem 20/2024)
di: Max E. Huber, et al.
Pubblicazione: (2024)

Investigation of Novel Isatinylhydantoin Derivatives as Potential Anti‐Kinetoplastid Agents
di: Keamogetswe Sechoaro, et al.
Pubblicazione: (2024)

Ligand‐Based Pharmacophore Modeling and Structure‐Based Virtual Screening for Identifying Potential Therapeutic Agents Targeting the SARS‐CoV‐2 Spike Protein‐ACE2 Receptor Interaction
di: Timoteo Delgado‐Maldonado, et al.
Pubblicazione: (2026)

Investigating the Ligand‐Binding Properties of N‐arylbenzimidazoles as Novel Elastase Inhibitors
di: Giovanna Pitasi, et al.
Pubblicazione: (2025)

Leveraging Natural Product‐Inspired Antifungals to Investigate the Mechanism of Action of Peniciaculin A
di: Ingrid K. Wilt, et al.
Pubblicazione: (2024)

Development of a Tumor Microenvironment‐Responsive Co(III)‐Chrysin Prodrug: Synthesis, Activation Profiling, and In Vitro Antineoplastic Evaluation
di: Prakash Shukla, et al.
Pubblicazione: (2025)